https://nuvigtx.com/nuvig-therapeutics-announces-first-patient-dosed-in-phase-2-cidp-trial-of-nvg-2089-and-presentation-of-phase-1-data/ 2025-09-09T19:45:38+00:00 https://nuvigtx.com/nuvig-therapeutics-appoints-david-j-woodhouse-ph-d-as-chief-executive-officer-and-james-mackay-ph-d-as-independent-board-chair/ 2025-09-09T19:45:38+00:00 https://nuvigtx.com/nuvig-launches-to-develop-novel-immune-therapeutics-for-chronic-inflammatory-and-autoimmune-diseases/ 2025-09-09T19:45:39+00:00 https://nuvigtx.com/nuvig-therapeutics-appoints-dr-alan-glicklich-chief-medical-officer/ 2025-09-09T19:45:39+00:00 https://nuvigtx.com/nuvig-initiates-clinical-development-of-next-generation-immune-modulator-nvg-2089/ 2025-09-09T19:45:39+00:00 https://nuvigtx.com/nuvig-therapeutics-announces-161-million-series-b-financing-and-progression-to-phase-2-development-with-novel-second-generation-immunomodulator/ 2025-09-09T19:45:39+00:00 https://nuvigtx.com/nuvig-therapeutics-appoints-celia-j-f-lin-m-d-as-chief-medical-officer/ 2025-11-18T16:04:43+00:00